Home › Research › Drug development
Semaglutide for obesity management: A narrative review of efficacy, safety, and future directions
Hajibandeh S, Tao YA, Hsieh MH, Liu HG, Cheng YF, Lee KH, Hsieh SY, Lu CH.. Journal of the American Pharmacists Association : JAPhA, 2026-04-21
Topic: Risk, prevention and care in population studies
Plain-language summary
Background Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), particularly semaglutide, have demonstrated substantial efficacy for glycemic control and weight management and are increasingly prescribed across diverse populations. Rapid expansion of indications, formulations, and real-world use has outpaced comprehensive evaluation of long-term safety, tolerability, and adherence, raising important concerns for clinical practice. Objective This narrative review aims to synthesize current evidence on the efficacy and safety profile of semaglutide, with a focus on adverse events, treatment persistence, perioperative considerations, and use in special populations, to support clinical decision-making and pharmacist-led patient care.
What this study adds
Evidence grade: High
This is a narrative review. This narrative review synthesizes current evidence on the efficacy and safety of semaglutide for obesity management, focusing on adverse events, treatment persistence, perioperative considerations and special populations. It does not address Alzheimer's disease treatment, cure or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Hajibandeh, S., Tao, Y. A., Hsieh, M. H., Liu, H. G., Cheng, Y. F., Lee, K. H., et al. (2026). Semaglutide for obesity management: A narrative review of efficacy, safety, and future directions. Journal of the American Pharmacists Association : JAPhA. https://doi.org/10.1016/j.japh.2026.103117
Vancouver
Hajibandeh S, Tao YA, Hsieh MH, Liu HG, Cheng YF, Lee KH, et al. Semaglutide for obesity management: A narrative review of efficacy, safety, and future directions. Journal of the American Pharmacists Association : JAPhA. 2026. doi:10.1016/j.japh.2026.103117. PMID: 42025961.
BibTeX
@article{hajibandeh2026-42025961,
author = {Hajibandeh, S. and Tao, Y. A. and Hsieh, M. H. and Liu, H. G. and Cheng, Y. F. and Lee, K. H. and Hsieh, S. Y. and Lu, C. H.},
title = {{Semaglutide for obesity management: A narrative review of efficacy, safety, and future directions}},
journal = {Journal of the American Pharmacists Association : JAPhA},
year = {2026},
doi = {10.1016/j.japh.2026.103117},
pmid = {42025961},
url = {https://doi.org/10.1016/j.japh.2026.103117}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Rapid expansion of indications, formulations, and real-world use has outpaced comprehensive evaluation of long-term safety, tolerability, and adherence, raising important concerns for clinical practice.
- Objective This narrative review aims to synthesize current evidence on the efficacy and safety profile of semaglutide, with a focus on adverse events, treatment persistence, perioperative considerations, and use in special populations, to support clinical decision-making and pharmacist-led patient care.
- Methods A review of clinical trials, observational studies, pharmacovigilance reports, regulatory communications, and professional guidelines was conducted.
- Evidence was drawn from randomized controlled trials, postmarketing safety reports, systematic reviews, and relevant clinical and regulatory documents.
Why it matters
This narrative review synthesizes current evidence on the efficacy and safety of semaglutide for obesity management, focusing on adverse events, treatment persistence, perioperative considerations and special populations. It does not address Alzheimer's disease treatment, cure or prevention.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designnarrative review
- Evidence strengthHigh
How this study scored 35/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of the American Pharmacists Association : JAPhA) |
| Journal's citation record | 1 / 4 | Journal of the American Pharmacists Association: journal h-index 82 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | Design recorded as “narrative review”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Chi‐Hua Lu: h-index 10 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Columbia University: institution h-index 1,824 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42025961) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 35 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Drug development from nearby years
Also in Drug development
104 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.